- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Cannabis Weekly Round-Up: Cookies Brand Makes Leap to Europe
Catch up on the latest announcements in the cannabis market.
This week, a popular cannabis brand based in the US marketplace confirmed an international plan for its products thanks to a new partnership.
Also during the period, a cannabinoid drug maker took a significant step forward with its current clinical trials, which are evaluating its candidate against pain related to cancer treatment.
Keep reading to find out more cannabis highlights from the past five days.
Popular adult-use brand signs international agreement
San Francisco-based cannabis brand company Cookies announced it will expand into the global market thanks to a new partnership with InterCure (NASDAQ:INCR,TSX:INCR.U), an Israeli cannabis firm.
“We look forward to reaching audiences in Austria and the United Kingdom and establishing Cookies as a mainstay in each community," Parker Berling, president of Cookies, said in a statement.
For his part, Alexander Rabinovitch, CEO of InterCure, praised the quality of the Cookies brand and said it was “only obvious” for these products to expand into more markets.
The details shared with investors indicate that InterCure will seek to set up stores and medical cannabis pharmacies both in Austria and the UK starting in 2022.
Specialized medical cannabis company shares encouraging data set
Cannabinoid drug-maker Tetra Bio-Pharma (TSX:TBP,OTCQB:TBPMF) told investors that cancer pain drug studies involving its candidate QIXLEEF returned positive initial results from two separate Phase 2 stage trials.
Dr. Guy Chamberland, CEO of the company, said the preliminary data from these studies backs up the information obtained during the Phase 1 stage.
"A safe and efficient therapeutic alternative that allows the reduction of opioids is critical now more than ever to support patients in their journey against pain,” Chamberland said.
Both studies from Tetra Bio-Pharma are being conducted in the US.
Cannabis company news
- Fire & Flower Holdings (TSX:FAF,OTCQX:FFLWF)will consolidate its publicly traded shares as it positions itself to gain a NASDAQ listing. Trevor Fencott, CEO of the firm, said this move represents a critical step for the company. “It enables Fire & Flower to qualify for a listing on the NASDAQ and expand its shareholder base,” he said.
- Columbia Care (NEO:CCHW,CSE:CCHW,OTCQX:CCHWF)confirmed the inclusion of its shares in the MSCI Canada Small Cap Index. “This is a landmark achievement for Columbia Care and the cannabis industry ... We appreciate the credibility and visibility that accompany inclusion in an MSCI index,” Nicholas Vita, CEO of Columbia Care said.
- Tilray (NASDAQ:TLRY,TSX:TLRY) launched a new medical cannabis product by way of oral strips with THC and CBD. Chairman and CEO Irwin Simon said the company expects these products to help with the company’s goal of being involved in “the growing expansion of medical cannabis across the globe.”
- Cronos Group (NASDAQ:CRON,TSX:CRON)issued a standardized report report to shareholders as part of its management cease trade order process.
Don't forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Bryan is a Senior Editor with INN. After graduating from the Langara journalism program he did some freelance reporting with community newspapers in British Columbia. He initially wrote about the life science space for INN and now spends his time covering the marijuana market, from Canadian LPs to US-based companies, and the impact of this sector on investors.
Learn about our editorial policies.